Abstracts Archive - Page 998 of 2425 - ACR Meeting Abstracts

Abstract Number: 655 • 2019 ACR/ARP Annual Meeting
Assessing Perceptions, Barriers, and Preferences to Exercise in Patients with Systemic Lupus Erythematosus
Gabriel Jeyasingham¹, Arzoo Alam ¹, Nicholas Steiner ², Kimberly Legault ¹, Mark Matsos ¹ and Karen Beattie ¹, ¹McMaster University, Hamilton, ON, Canada, ²Western University, London, ON, Canada
Background/Purpose: Cardiovascular disease is a significant cause of mortality in patients with SLE. High levels of fatigue are also reported in patients with SLE and…
Abstract Number: 656 • 2019 ACR/ARP Annual Meeting
Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis
Vanessa Castro Coello¹, Alejandro Brigante ², Sabrina Porta ³, Paola Avila ³, Marina Micelli ⁴, Adriana Hamaui ⁵, Eduardo Kerzberg ⁶ and Diana Dubinsky ⁵, ¹Sanatorio Güemes, Buenos Aires, Buenos Aires, Argentina, ²Sanatorio Güemes, Servicio de Medicina Interna – Reumatología, Francisco Acuña de Figueroa 1240, C1180AAD, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina, ⁴Hospital General de Agudos Dr. José M. Ramos Mejía, Buenos Aires, Argentina, ⁵Sanatorio Güemes, Buenos Aires, Argentina, ⁶Hospital Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: End-stage renal disease (ESRD) develops in 10-30% of patients with lupus nephritis (LN) despite standard treatment. A biomarker with excellent sensitivity and specificity to…
Abstract Number: 657 • 2019 ACR/ARP Annual Meeting
Performance of the “Do You Know What I Mean” Questionnaire in the Assessment of Disease Knowledge in Patients with Systemic Lupus Erythematosus
Eliana Serrano¹, Silvana Pérez ², Juan Bande ², Julia Sosa ¹, María Kohan ², Diana Klajn ², María Medina ², Silvia Papasidero ², José Caracciolo ², María Leguizamón ³, Susana Mazza ³, Yessika Soria Curi ³, Francisco Huttmann ³, Verónica Bellomio ³, Carla Matellan ⁴, Marina Micelli ⁵, Eduardo Kerzberg ⁶, Claudia Peon ⁷, Dario Mata ⁸, Carolina Ayelen Isnardi ⁹, Dafne Capelusnik ¹⁰, Yohena Victor ¹¹, Analía Alvarez ¹¹, Maximiliano Machado Escobar ¹², María Yacuzzi ¹², Veronica Saurit ¹³, Natalia Cucchiaro ¹⁴, María Crespo Espíndola ¹⁴, Grace Loayza Reynolds ¹⁵, Yanina Bottinelli ¹⁵, Gabriela Garate Correa ¹⁶, Ramiro Gomez ¹⁷, Diana Dubinsky ¹⁸, María de la Torre ¹⁹, Cecilia Pisoni ¹⁹ and Adriana García Coello ²⁰, ¹Hospital General de Agudos Dr. E. Tornú, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, ²Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ³Hospital Ángel C. Padilla, San Miguel de Tucumán, Tucuman, Argentina, ⁴Hospital General de Agudos Dr. José M. Ramos Mejia, Ciudad Autónoma de Buenos, Buenos Aires, Argentina, ⁵Hospital General de Agudos Dr. José M. Ramos Mejía, Buenos Aires, Argentina, ⁶Hospital General de Agudos Dr. José M. Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Hospital Dr. Cosme Argerich, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Cosme Argerich, Buenos Aires, Argentina, ⁹Instituto de Rehabilitación Psicofísica, Ciudad de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ¹⁰Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ¹¹Hospital General de Agudos José M. Penna, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ¹²Hospital Eva Perón, San Miguel de Tucumán, Tucuman, Argentina, ¹³Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ¹⁴Hospital Señor del Milagro, Salta, Salta, Argentina, ¹⁵Hospital Posadas, El Palomar, Buenos Aires, Argentina, ¹⁶Sanatorio Güemes, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ¹⁷Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ¹⁸Sanatorio Güemes, Buenos Aires, Argentina, ¹⁹Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²⁰Hospital General de Agudos Dr. Ignacio Pirovano, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: ‘Do you know what I mean?’ is a self-reported questionnaire developed to assess disease knowledge level in Systemic lupus erythematosus (SLE) patients. It is…
Abstract Number: 658 • 2019 ACR/ARP Annual Meeting
Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study
Sarah Dyball¹, John Reynolds ², Hector Chinoy ², Tracy Briggs ², Sahena Haque ³, Eoghan McCarthy ⁴, Ellen Bruce ⁵, Ariane Herrick ⁶, Ian Bruce ⁷ and Ben Parker ⁸, ¹University of Manchester, Manchestser, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³University Hospital South Manchester, Manchester, United Kingdom, ⁴Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Central Manchester University Hospitals, Manchester, United Kingdom, ⁶Salford Royal Foundation Trust, Manchester, United Kingdom, ⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁸University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs) are a heterogeneous group of diseases with overlapping clinical features and shared immunopathology. In routine practice, a clinician diagnosis is…
Abstract Number: 659 • 2019 ACR/ARP Annual Meeting
Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
Sabine Zenz¹, Barbara Dreo ¹, Angelika Lackner ¹, Barbara Prietl ², Selina Kofler ², Harald Sourij ², Florentine Moazedi-Fuerst ¹, Monica D'Orazio ¹, Martin Stradner ¹, Winfried Graninger ¹ and Hans-Peter Brezinschek ¹, ¹Department of Internal Medicine/Division of Rheumatology and Immunology, Graz, Austria, ²2CBmed GmbH – Center for Biomarker Research in Medicine, Graz, Austria
Background/Purpose: B-cells play a pivotal role in the initiation and perpetuation of systemic lupus erythematosus (SLE). Recently, it has been demonstrated that in active SLE…
Abstract Number: 660 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease
Leyre Riancho-Zarrabeitia¹, Víctor M Martinez-Taboada ², Iñigo Rua Figueroa ³, Fernando Alonso ⁴, María Galindo ⁵, Juan Ovalles-Bonilla ⁶, Alejandro Olivé-Marqués ⁷, Antonio Fernández-Nebro ⁸, Jaime Calvo-Alen ⁹, Raul Menor Almagro ¹⁰, Eva Tomero-Muriel ¹¹, Esther Uriarte Isacelaya ¹², Alina Boteanu ¹³, Mariano Andrés ¹⁴, Mercedes Freire González ¹⁵, Gregorio Santos Soler ¹⁶, Esther Ruiz Lucea ¹⁷, Monica Ibañez Barcelo ¹⁸, Ivan Castellvi ¹⁹, Carles Galisteo ²⁰, Víctor Quevedo Vila ²¹, Enrique Raya ²², Javier Narváez ²³, Lorena Expósito ²⁴, José A Hernández-Beriain ²⁵, Loreto Horcada Rubio ²⁶, Elena Aurrecoechea ²⁷ and Jose Maria Pego-Reigosa ²⁸, ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Valdecilla, Santander, ³Hospital Doctor Negrin, Las Palmas, ⁴Unidad Investigación SER, Madrid, Spain, ⁵Hospital 12 De Octubre, Madrid, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital German Trias i Pujol, Badalona, Spain, ⁸Hospital Carlos Haya, Malaga, Spain, ⁹Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ¹⁰Hospital Universitario de Jerez, Puerto De Santa María, Spain, ¹¹Hospital Universitario La Princesa, Madrid, Spain, ¹²Hospital Universitario Donosti, San Sebastian, Spain, ¹³Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, Spain, ¹⁷Hospital Universitario Basurto, Bilbao, Spain, ¹⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Parc Taulí, Barcelona, Catalonia, Spain, ²¹Hospital Comarcal Monforte, Monforteº, Spain, ²²Hospital Universitario Clínico San Cecilio, Granada, Spain, ²³Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ²⁴Hospital Universitario de Canarias, Las Palmas, Spain, ²⁵Hospital Insular Universitario de Gran Canaria, Las Palmas, Spain, ²⁶Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁷Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²⁸Complexo Hospitalario Universitario, Vigo, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in SLE patients. Our aim was to investigate the differences between SLE…
Abstract Number: 661 • 2019 ACR/ARP Annual Meeting
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
SAFAK MIRIOGLU ¹, SUZAN CINAR ², Halil Yazici ³, Ahmet Gül ⁴, Lale Öcal ⁴, Murat Inanc ⁴ and Bahar Artim-Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, ISTANBUL, Turkey, ²Istanbul University,Department of Immunology, Institute of Experimental Medicine, ISTANBUL, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: TWEAK, MCP-1 and NGAL, mediators in pathogenesis of systemic lupus erythematosus (SLE), are proinflammatory cytokines/chemokines that are thought as potential biomarkers reflecting disease activity.…
Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Brooke Williams¹, Bridget Muckian ¹, Claire Dykas ², Christine Peschken ³, Richard Furie ⁴, Elena Massarotti ⁵, Vanja sikirica ⁶, Steven Gilbert ⁷, Martin Hodge ⁷ and Peter Lipsky ⁸, ¹AMPEL BioSolutions, Charlottesville, VA, ²AmpelBioSolutions, Charlottesville, VA, ³University of Manitoba, Winnepeg, Canada, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Pfizer, Boston, MA, ⁷Pfizer, Boston, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…
Abstract Number: 663 • 2019 ACR/ARP Annual Meeting
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Hayam ElAggan¹, Nahla Farahat ¹, Mohamed Sakr ¹ and Shaymaa Tawfik ¹, ¹Faculty of Medicine, University of Alexandria, Alexandria, Egypt, Alexandria, Egypt
Background/Purpose: Toll-like receptor 7 (TLR7) can sense single-stranded RNA with subsequent induction of different interferon (IFN) types including IFN lambda (IFNL) and may contribute to…
Abstract Number: 664 • 2019 ACR/ARP Annual Meeting
Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus
Wietske Lambers¹, Karina de Leeuw ², Femke Homan ¹, Berber Doornbos-van der Meer ¹, Hendrika Bootsma ³, Johanna Westra ² and Gilles Diercks ¹, ¹UMCG, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous auto-inflammatory skin disease, that is driven to a great extent by interferon (IFN) type I1, and is…
Abstract Number: 665 • 2019 ACR/ARP Annual Meeting
Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia
Warren Raymond¹, Alexandra Kang ², Daniel Wong ³, Aron Chakera ⁴ and Johannes Nossent ¹, ¹School of Medicine, The University of Western Australia, Crawley, Western Australia, Australia, ²PathWest, Nedlands, Western Australia, Australia, ³PathWest, Perth, Western Australia, Perth, Western Australia, Australia, ⁴Renal Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Background/Purpose: The role of repeat renal biopsy (RRBx) in lupus nephritis (LN) to guide treatment or predict prognosis is not fully understood. We assessed the…
Abstract Number: 666 • 2019 ACR/ARP Annual Meeting
Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
William Fung¹, Mitra Moazzami ², Lisa Engel ³, Jiandong Su ⁴, Dennisse Bonilla ⁴, Pooneh Akhavan ⁵, Patricia Katz ⁶, Dorcas Beaton ⁷ and Zahi Touma ⁸, ¹University of Toronto, Toronto, ON, Canada, ²George Washington University, Washington, DC, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, Canada, ⁶University of California, San Francisco, san francisco, CA, ⁷St. Michael's Hospital, Toronto, ON, Canada, ⁸University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Patient-reported outcomes (PROs) measures are a key component of the care of patients with systemic lupus erythematosus (SLE). The Patient Reported Outcomes Measurement Information…
Abstract Number: 667 • 2019 ACR/ARP Annual Meeting
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Nathaniel Harris¹, Amanda Eudy ², Megan Clowse ², Lisa Criscione-Schreiber ², Jayanth Doss ², Rebecca Sadun ², Jennifer Rogers ² and Kai Sun ², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham
Background/Purpose: We have developed a new conceptual model that characterizes lupus into subtypes based on physician- and patient-reported measures: Type 1 is assessed by the…
Abstract Number: 668 • 2019 ACR/ARP Annual Meeting
Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population
J. Patricia Dhar¹, Louis Saravolatz ² and Susan Szpunar ³, ¹Wayne State University, Bloomfield Hills, MI, ²Ascension St. John Hospital and Wayne State University, Grosse Pointe Woods, MI, ³Ascension St. John Hospital Hospital, Grosse Pointe Woods, MI
Background/Purpose: Women with SLE are at increased risk for cervical neoplasia likely because of infection with high risk (HR) HPV and thus should be considered…
Abstract Number: 669 • 2019 ACR/ARP Annual Meeting
Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
Rosalind Ramsey-Goldman¹, Roberta Alexander ², Sonali Narain ³, Cristina Arriens ⁴, Elena Massarotti ⁵, Daniel Wallace ⁶, Amit Saxena ⁷, Christopher Collins ⁸, Chaim Putterman ⁹, Kenneth Kalunian ¹⁰, Tyler O'Malley ¹¹, Armida Sace ², Rowena LaFon ², Jo-Anne Ligayon ², Claudia Ibarra ², John Conklin ², Thierry Dervieux ² and Arthur Weinstein ¹², ¹Northwestern University, Chicago, IL, ²Exagen, Vista, CA, ³Northwell Health, Great Neck, Long Island, NY, ⁴Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ⁷New York University School of Medicine, New York, NY, ⁸MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁹Albert Einstein College of Medicine, New York, NY, ¹⁰Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹¹Exagen, Oceanside, CA, ¹²Georgetown University & Exagen, Inc, Claremont, CA
Background/Purpose: We reported (Ramsey-Goldman et al., Arthritis Rheumatol 2018: 70 [suppl 10]) that cell-bound complement activation products (CB-CAPs) and a multi-analyte assay panel with algorithm…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].